share_log

Private Companies Among KPC Pharmaceuticals,Inc's (SHSE:600422) Largest Stockholders and Were Hit After Last Week's 7.7% Price Drop

Private Companies Among KPC Pharmaceuticals,Inc's (SHSE:600422) Largest Stockholders and Were Hit After Last Week's 7.7% Price Drop

私人公司是KPC藥品公司(SHSE:600422)的最大股東之一,上週股價下跌了7.7%,遭受重創。
Simply Wall St ·  06/25 18:26

Key Insights

  • Significant control over KPC PharmaceuticalsInc by private companies implies that the general public has more power to influence management and governance-related decisions
  • A total of 10 investors have a majority stake in the company with 51% ownership
  • Institutions own 25% of KPC PharmaceuticalsInc

Every investor in KPC Pharmaceuticals,Inc (SHSE:600422) should be aware of the most powerful shareholder groups. We can see that private companies own the lion's share in the company with 37% ownership. Put another way, the group faces the maximum upside potential (or downside risk).

And last week, private companies endured the biggest losses as the stock fell by 7.7%.

Let's delve deeper into each type of owner of KPC PharmaceuticalsInc, beginning with the chart below.

ownership-breakdown
SHSE:600422 Ownership Breakdown June 25th 2024

What Does The Institutional Ownership Tell Us About KPC PharmaceuticalsInc?

Institutional investors commonly compare their own returns to the returns of a commonly followed index. So they generally do consider buying larger companies that are included in the relevant benchmark index.

KPC PharmaceuticalsInc already has institutions on the share registry. Indeed, they own a respectable stake in the company. This suggests some credibility amongst professional investors. But we can't rely on that fact alone since institutions make bad investments sometimes, just like everyone does. When multiple institutions own a stock, there's always a risk that they are in a 'crowded trade'. When such a trade goes wrong, multiple parties may compete to sell stock fast. This risk is higher in a company without a history of growth. You can see KPC PharmaceuticalsInc's historic earnings and revenue below, but keep in mind there's always more to the story.

earnings-and-revenue-growth
SHSE:600422 Earnings and Revenue Growth June 25th 2024

KPC PharmaceuticalsInc is not owned by hedge funds. The company's largest shareholder is China Resources Company Limited, with ownership of 28%. Hongta Tobacco (Group) Co., Ltd. is the second largest shareholder owning 7.9% of common stock, and Fullgoal Fund Management Co. Ltd. holds about 4.3% of the company stock.

We did some more digging and found that 10 of the top shareholders account for roughly 51% of the register, implying that along with larger shareholders, there are a few smaller shareholders, thereby balancing out each others interests somewhat.

While studying institutional ownership for a company can add value to your research, it is also a good practice to research analyst recommendations to get a deeper understand of a stock's expected performance. There are a reasonable number of analysts covering the stock, so it might be useful to find out their aggregate view on the future.

Insider Ownership Of KPC PharmaceuticalsInc

The definition of company insiders can be subjective and does vary between jurisdictions. Our data reflects individual insiders, capturing board members at the very least. The company management answer to the board and the latter should represent the interests of shareholders. Notably, sometimes top-level managers are on the board themselves.

I generally consider insider ownership to be a good thing. However, on some occasions it makes it more difficult for other shareholders to hold the board accountable for decisions.

Our data suggests that insiders own under 1% of KPC Pharmaceuticals,Inc in their own names. But they may have an indirect interest through a corporate structure that we haven't picked up on. It is a pretty big company, so it would be possible for board members to own a meaningful interest in the company, without owning much of a proportional interest. In this case, they own around CN¥53m worth of shares (at current prices). Arguably, recent buying and selling is just as important to consider. You can click here to see if insiders have been buying or selling.

General Public Ownership

The general public-- including retail investors -- own 36% stake in the company, and hence can't easily be ignored. While this size of ownership may not be enough to sway a policy decision in their favour, they can still make a collective impact on company policies.

Private Company Ownership

Our data indicates that Private Companies hold 37%, of the company's shares. It's hard to draw any conclusions from this fact alone, so its worth looking into who owns those private companies. Sometimes insiders or other related parties have an interest in shares in a public company through a separate private company.

Next Steps:

While it is well worth considering the different groups that own a company, there are other factors that are even more important. Case in point: We've spotted 1 warning sign for KPC PharmaceuticalsInc you should be aware of.

But ultimately it is the future, not the past, that will determine how well the owners of this business will do. Therefore we think it advisable to take a look at this free report showing whether analysts are predicting a brighter future.

NB: Figures in this article are calculated using data from the last twelve months, which refer to the 12-month period ending on the last date of the month the financial statement is dated. This may not be consistent with full year annual report figures.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論